http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1835289-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3244ba8390b1f290f4ba36389c82488b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-58 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate | 2006-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38db1f9c34995950d9bdf3939ad143c7 |
| publicationDate | 2007-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1835289-A1 |
| titleOfInvention | Means and methods for predicting cardiovascular complications in subjects suffering from osteoporosis |
| abstract | The present invention relates to a method of predicting whether a subject suffering from a bone mineral disorder (e.g. osteoporosis) is at risk of developing cardiovascular complications comprising determining the amount of a natriuretic peptide in a sample of said subject and predicting whether the said subject is at risk of developing cardiovascular complications by comparing the amount to a reference amount. Moreover, the method relates to devices and kits for carrying out said method. The preferred natriuretic peptide marker is proBNP. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011022552-A3 |
| priorityDate | 2006-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 193.